Traduction de «data expected » (Néerlandais → Français) :

Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated. In addition to these 74 indicators, 11 indicators for which data are expected
Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated.

The late-stage pipeline is also progressing quickly: European regulatory approval expected soon for QAB149 (COPD), while further positive Phase III data presented in September 2009 reaffirmed the potential of FTY720 (MS).
Le pipeline de médicaments en phase ultime de développement progresse également avec rapidité. En effet, l’homologation de QAB149 (BPCO) est attendue sous peu tandis que de nouveaux résultats positifs de phase III présentés en septembre 2009 ont confirmé le potentiel de FTY720 (SEP).

11] Radionuclides for therapeutic applications : biological and medical aspects (present status, development and expectations) A. Wambersie, R.A. Gahbauer, IAEA- Nuclear Data 2002.
11] Radionuclides for therapeutic applications : biological and medical aspects (present status, development and expectations) A. Wambersie, R.A. Gahbauer, IAEA-Nuclear Data 2002.

In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.
In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.

- Regulatory feedback expected in Q4 2010 Q4 2008 Approved Q3 2010 - Clinical trials to address US Food and Drug Administration (FDA) complete response letter (October 2009) completed in Q3 and data generated from these trials was submitted to the FDA in late September
2010 T4 2008 Autorisé T3 2010 - Essais cliniques pour répondre à la «complete response letter» de la FDA (oct. 2009) achevés au T3 et données soumises à fin septembre à la FDA

- ENESTnd 24 month median follow-up data expected to be presented at the American Society of Hematology in December
- Présentation attendue en décembre des résultats du suivi sur 24 mois de l’étude ENESTnd devant la Société américaine d’hématologie

Data from the ASPIRE HIGHER outcomes program and various single-pill combinations with other medicines are expected to drive future growth.
Les données du programme de résultats ASPIRE HIGHER et diverses associations avec d’autres médicaments en un comprimé unique devraient soutenir sa croissance future.

ASA404 2 nd line non-small cell 2012 III - Interim analysis in H2 2010 lung cancer BAF312 Multiple sclerosis ≥2014 II - Phase II data expected in Q4 2010
Psoriasis 2013 II - Début de la phase III prévu en 2011 Arthrite rhumatoïde 2013 II - Début de la phase III prévu à fin 2010 2 e intention dans le 2012 III - Analyse intermédiaire au S2 2010 cancer du poumon à non petites cellules

Regulatory filings are expected this year in pancreatic neuroendocrine tumors (pNET) following data showing Afinitor met the primary endpoint of progression-free survival in a Phase III study of pNET.
A la suite de résultats d’une étude de phase III consacrée aux tumeurs neuroendocrines du pancréas (pTNE) montrant qu’Afinitor satisfaisait au critère principal de survie sans progression de la maladie, des demandes d’autorisation devraient être déposées cette année.